ALB and diabetic kidney disease: We examined whether sodium-glucose cotransporter 2 (SGLT2) inhibition added to angiotensin receptor blockade is associated with slower eGFR decline in this phenotype.<h4>Methods</h4>In this retrospective cohort, adults with type 2 diabetes and a non-albuminuric DKD phenotype (urine albumin-to-creatinine ratio (UACR) <30 mg/g on serial testing, with prespecified evidence supporting DKD when baseline eGFR was 60-89 mL/min/1.73 m<sup>2</sup>) were grouped as concurrent empagliflozin plus telmisartan (n=60) or telmisartan-based care without any SGLT2 inhibitor (n=60).